Why do some Low-Risk leukemia patients relapse? scientists look to bone marrow cells for answers
NCT ID NCT07379528
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study looked at bone marrow stem cells from 70 adults with acute myeloid leukemia (AML) who had a favorable genetic marker (NPM1 mutation). The goal was to understand why more than half of these patients still relapse despite having a good prognosis. Researchers analyzed the mesenchymal stem cells in the bone marrow to see if they help protect leukemia cells from chemotherapy. This is a knowledge-gathering study, not a treatment trial.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this research could help doctors better predict which low-risk AML patients will relapse, leading to more personalized monitoring or treatment.
What could go wrong
This is an observational study, not a treatment trial. It only looks at cells in the lab, so it cannot directly improve patient outcomes. Results may not change clinical practice.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKAEMIA (AML) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fondazione IRCCS Policlinico San Matteo
Pavia, Pavia, 27100, Italy